Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIRAGE: VCN-01 plus Nab-Paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
NCT05673811Phase 2Completed
- Sponsor
- Theriva Biologics
- Start
- Jan 2023
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of zabilugene almadenorepvec in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Theriva Biologics. Primary endpoints: Overall Survival at 27 months and Treatment-Emergent Adverse Events. Started Jan 2023; status: completed.
02
Drugs
zabilugene almadenorepvec
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05673811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673811.